Anne Catrien Baakman

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis

Guido van Amerongen, Kawita M. S. Kanhai, Anne Catrien Baakman et al. · Clinical Therapeutics · 2017 · 78 citations · Full text

Cannabis Use, Pain Disorders, Neurological Assessment +14

First in human study with a prodrug of galantamine: Improved benefit‐risk ratio?

Anne Catrien Baakman, Ellen 't Hart, Denis G. Kay et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2016 · 22 citations · Full text

Model‐based exposure‐response analysis to quantify age related differences in the response to scopolamine in healthy subjects

Ricardo Álvarez-Jiménez, Geert Jan Groeneveld, Joop van Gerven et al. · British Journal of Clinical Pharmacology · 2016 · 21 citations · Full text

An anti‐nicotinic cognitive challenge model using mecamylamine in comparison with the anti‐muscarinic cognitive challenge using scopolamine

Anne Catrien Baakman, Ricardo Álvarez-Jiménez, Erica S. Klaassen et al. · British Journal of Clinical Pharmacology · 2017 · 20 citations · Full text

Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease

Anne Catrien Baakman, Carmen Gavan, Lotte van Doeselaar et al. · British Journal of Clinical Pharmacology · 2021 · 17 citations · Full text